We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Discovered for Pregnancy-Related Heart Disease

By LabMedica International staff writers
Posted on 16 May 2013
A molecule has been identified that can serve as a biomarker for peripartum cardiomyopathy that occurs in pregnant women during the last month or in the months following their pregnancy.

The molecule is a micro-ribonucleic acid (miRNA) which is induced by the nursing hormone prolactin and detection in the blood, protected from endogenous ribonuclease (RNase) activity by exosomes, has emerged as a promising diagnostic tool.

Scientists at the University of Liege (Belgium) obtained plasma samples from 38 patients with peripartum cardiomyopathy (PPCM) at their first presentation and from18 healthy nursing women, from five age-matched healthy controls, from 30 patients with heart failure due to dilated cardiomyopathy (DCM), and from patients with PPCM receiving bromocriptine. More...


The investigators found the expression miRNA miR-146a was induced by the nursing hormone prolactin. MiR-146a expression promoted vascular damage and was increased in a mouse model of PPCM. Conversely, loss of miR-146a in mice prevented PPCM. Plasma levels of miR-146a were significantly higher in patients with acute PPCM compared with healthy postpartum controls. Levels of miR-146a were not significantly different between healthy postpartum controls and healthy nonpregnant women. Compared with 30 patients with a similar degree of heart failure due to DCM and with no history of PPCM, miR-146a levels were significantly higher in the PPCM group.

The results of this study indicate that miR-146a mediates antiangiogenic effects of 16-kDa N-terminal prolactin fragment (16K PRL) in endothelial cells and the slowing of metabolism in cardiomyocytes. In addition, this microRNA may serve as a highly specific blood biomarker useful for diagnosis and risk stratification of patients with peripartum heart failure and appears to be a specific biomarker of PPCM. The study was published on April 24, 2013, in the Journal of Clinical Investigation.

Related Links:

University of Liege




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.